[1]张莹莹,王振光,武凤玉,等.特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析[J].国际放射医学核医学杂志,2016,40(6):414-418.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
　Zhang Yingying,Wang Zhenguang,Wu Fengyu,et al.18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):414-418.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
点击复制

特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第6期
页码:
414-418
栏目:
论著
出版日期:
2016-11-25

文章信息/Info

Title:
18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients
作者:
张莹莹;  王振光;  武凤玉;  刘思敏
266000, 青岛大学附属医院PET/CT中心
Author(s):
Zhang Yingying;  Wang Zhenguang;  Wu Fengyu;  Liu Simin
PET/CT Center, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
关键词:
特发性肺纤维化; 正电子发射断层显像术; 体层摄影术; X线计算机; 氟脱氧葡萄糖F18
Keywords:
Idiopathic pulmonary fibrosis; Positron-emission tomography; Tomography;  X-ray computed; Flurodeoxyglucose F18
DOI:
10.3760/cma.j.issn.1673-4114.2016.06.003
摘要:
目的 对比分析特发性肺间质纤维化（IPF）高分辨率CT（HRCT）上病变区域和非病变区域的PET/CT表现及其诊断价值。方法 按照IPF的临床诊断标准，选取接受PET/CT检查并有完整资料的IPF病例及健康体检者各27例，规定病变区域为HRCT上表现为磨玻璃密度影、网格影及蜂窝影等区域，非病变区域为肉眼可观察到的密度低于病变区的最小密度区，测定病变区域的SUVmax，分别在IPE组非病变区域和对照组肺部HRCT横断面图像上画取ROI，测量其CT值，并在PET/CT图像相应位置画取ROI，测量SUVmax、平均标准化摄取值（SUVmean），计算与纵隔大血管主动脉弓血池（SUVmax、SUVmean）比值：肺组织/纵隔血池最大摄取比（LT/MBmax）和肺组织/纵隔血池平均摄取比（LT/MBmean）。采用独立样本t检验比较组间LT/MBmax、LT/MBmean及CT值差异。结果 IPF组27例患者，其中肺部表现为磨玻璃密度影14例、网格影27例、蜂窝影13例，同一患者可有多种表现，以上表现均为放射性摄取增高，SUVmax值为2.32±1.10。IPF组非病变区域LT/MBmax（0.44±0.55 vs.0.32±0.05）和LT/MBmean（0.55±0.38 vs.0.33±0.05）均高于对照组（t=5.87和2.89，P均<0.05）；但两组CT值（-836.59±32.33 vs.-837.99±29.90）比较，差异无统计学意义（t=-0.15，P>0.05）。结论 IPF患者HRCT上显示的病变区与非病变区对18F-FDG摄取均增加，PET/CT在IPF诊断及治疗监测方面有一定优势。
Abstract:
Objective To compare and analyze the PET signals at regions with abnormal and normal pulmonary parenchyma on high resolution CT(HRCT) in idiopathic pulmonary fibrosis(IPF) patients to explore the diagnostic value of PET/CT. Methods According to the standards for the clinical diagnosis of IPF, a total of 27 IPF patients(21 men and 6 women) and 27 control populations(19 men and 8 women) were randomly selected and recruited for PET/CT. The abnormal regions were described to show ground-glass appearance, reticulation, honeycombing, and so on. Normal regions corresponding to areas of minimal observed density were noted as distinct from the abnormal regions. The maximal standard uptake value(SUVmax) of the abnormal regions was measured. The ROI in HRCT images of the control population was placed in areas of each lung that were considered morphologically normal to measure the CT densities. The ROI was selected in PET/CT images at corresponding locations; the SUVmax and mean standard uptake value(SUVmean) were measured and used to calculate the aortic blood pool of mediastinal large blood vessels. The LT/MBmax, LT/MBmean, and CT densities of each ROI were analyzed by the independent sample t-test. Results Increased pulmonary 18F-FDG uptake was observed in 27 of 27 patients. The parenchymal patterns on HRCT at the site of high metabolism were ground-glass appearance(14/27), reticulation(27/27), and honeycombing(13/27). The LT/MBmax in the normal lung parenchyma of IPF patients was higher than in the control population[(0.44±0.55 vs. 0.32±0.05); t=5.87, P<0.05]. The LT/MBmean in normal lung parenchyma of IPF was higher than in the controls[(0.55±0.38 vs. 0.33±0.05); t=2.89, P<0.05]. The CT densities in normal lung parenchyma of IPF and control population were not significantly different[(-836.59±32.33 vs. -837.99±29.90); t=-0.15, P>0.05]. Conclusions IPF patients showed increased pulmonary uptake of 18F-FDG on PET in lung regions with abnormal and normal morphological appearances on HRCT. Therefore, PET/CT gives superior diagnosis and therapeutic monitoring.

参考文献/References:

[1] 美国胸科学会, 欧洲呼吸学会, 日本呼吸学会, 等.特发性肺纤维化诊治循证指南(摘译本)[J].中华结核和呼吸杂志, 2011, 34(7):486-494. DOI:10.3760/cma.j.issn.1001-0939.2011.07.005.American Thoracic Society, European Respiratory Society, the Japanese Respiratory Society, et al.Idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management(pick version)[J].Chin J Tuberc Respir Dis, 2011, 34(7):486-494.
[2] Takimoto T, Sasada S, Yamadori T, et al.A case of adenocarcinoma of lung with idiopathic pulmonary fibrosis, showing 18-fluorodeo-xyglucose uptake in positron emission tomography[J].Nihon Kokyuki Gakkai Zasshi, 2008, 43(4):258-262. DOI:10.1111/j.1365-2958.2008.06208.x.
[3] Meissner HH, Soo Hoo GW, Khonsary SA, et al.Idiopathic pulmonary fibrosis:evaluation with positron emission tomography[J].Respiration, 2006, 73(2):197-202. DOI:10.1159/000088062.
[4] Groves AM, Win T, Screaton NJ, et al.Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease:implications from initial experience with 18F-FDG PET/CT[J].J Nucl Med, 2009, 50(4):538-545. DOI:10.2967/jnumed.108.057901.
[5] El-Chemaly S, Malide D, Yao J, et al.Glucose transporter-1 distribution in fibrotic lung disease:association with[18F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization[J].Chest, 2013, 143(6):1685-1691. DOI:10.1378/chest.12-1359.
[6] Nusair S, Rubinstein R, Freedman NM, et al.Positron emission tomography in interstitial lung disease[J].Respirology, 2007, 12(6):843-847. DOI:10.1111/j.1440-1843.2007.01143.x.
[7] Bondue B, Sherer F, Van Simaeys GA, et al.PET/CT with 18F-FDG-and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis[J].J Nucl Med, 2015, 56(1):127-132. DOI:10.2967/jnumed.114.147421.
[8] Kambouchner M, Levy P, Nicholson AG, et al.Prognostic relevance of histological variants in nonspecific interstitial pneumonia[J].Histopathology, 2014, 65(4):549-560. DOI:10.1111/his.12415.
[9] Tabaj GC, Fernandez CF, Sabbagh E, et al.Histopathology of the idiopathic interstitial pneumonias(ⅡP):A review[J].Respirology, 2015, 20(6):873-883. DOI:10.1111/resp.12551.
[10] 杨雪梅, 王兴胜, 崔社怀.肌成纤维细胞在肺纤维化中的来源和作用[J].国际病理科学与临床杂志, 2008, 28(1):54-58. DOI:10.3969/j.issn.1673-2588.2008.01.013.Yang XM, Wang XS, Cui SH.Origin and role of myofibroblast in pulmonary fibrosis[J].Inter J Pathol Clini Med, 2008, 28(1):54-58.
[11] Umeda Y, Demura Y, Ishizaki T, et al.Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia[J].Eur J Nucl Med Mol Imaging, 2009, 36(7):1121-1130. DOI:10.1007/s00259-009-1069-1.
[12] Win T, Lambrou T, Hutton BF, et al.18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible:implications for future clinical trials[J].Eur J Nucl Med Mol Imaging, 2012, 39(3):521-528. DOI:10.1007/s00259-011-1986-7.
[13] Win T, Thomas BA, Lambrou T, et al.Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients[J].Eur J Nucl Med Mol Imaging, 2014, 41(2):337-342. DOI:10.1007/s00259-013-2514-8.
[14] Bitterman PB, Rennard SI, Keogh BA, et al.Familial idiopathic pulmonary fibrosis:evidence of lung inflammation in unaffected family members[J].N Engl J Med, 1986, 314(21):1343-1347. DOI:10.1056/NEJM198605223142103.

相似文献/References:

[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
　He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
　Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
　Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
　Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
　Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
　Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
　Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
　You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
　Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
　Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]

备注/Memo

备注/Memo:
收稿日期:2016-05-12。
通讯作者:王振光,Email:wangzhenguang@aliyun.com
更新日期/Last Update: 1900-01-01